Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
J&J in $1 billion deal to bolster prostate-cancer focus
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.